COLLEGIUM PHARMACEUTICAL, INC — Earnings Release 2017

May 10, 2017

8-K 1 a17-12892_18k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest reported): May 10, 2017

COLLEGIUM PHARMACEUTICAL, INC.

(Exact Name of Registrant as Specified in Charter)

Virginia	001-37372	03-0416362
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

780 Dedham Street

Suite 800

Canton, MA 02021

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 713-3699

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period or complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

SEQ.=1,FOLIO='',FILE='C:\JMS\109765\17-12892-1\task8430772\12892-1-ba.htm',USER='109765',CD='May 11 00:27 2017'

Item 2.02 Results of Operations and Financial Condition.

On May 10, 2017, Collegium Pharmaceutical, Inc. issued a press release announcing its financial results for the quarterly period ended March 31, 2017. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits :

Exhibit No.	Description
99.1	Press Release dated May 10, 2017.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\109765\17-12892-1\task8430772\12892-1-ba.htm',USER='109765',CD='May 11 00:27 2017'

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Paul Brannelly
Name:	Paul Brannelly
Title:	Executive Vice President and Chief
	Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\109765\17-12892-1\task8430772\12892-1-ba.htm',USER='109765',CD='May 11 00:27 2017'

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated May 10, 2017.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\109765\17-12892-1\task8430772\12892-1-ba.htm',USER='109765',CD='May 11 00:27 2017'